ArticleGynecologic oncology reports2026
Consideration for HPV vaccination recommendations in patients with vulvar dysplasia and malignancy following resection: A retrospective study investigating rural-urban vaccination practices in patients served by an academic medical center in the heartland.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The American College of Obstetricians and Gynecologists (ACOG) recommends the HPV vaccine for unvaccinated or incompletely vaccinated individuals as an adjuvant treatment for cervical intraepithelial neoplasia (CIN) 2 + . Due to no such recommendation for adjuvant HPV vaccination for patients with vulvar intraepithelial neoplasia (VIN) 2 + after resection, and due to the large catchment area of our institution comprising rural and urban patient populations, which are disproportionately affected by HPV-associated cancers, we examined HPV vaccination uptake in patients with VIN2 + and vulvar malignancy and assessed relationships between social vulnerability and rurality. Methods: We performed a retrospective analysis of patients treated between 2018 and 2023 at a single Midwestern academic medical center. The study analyzed clinical and demographic data along with the associated social vulnerability index (SVI) and Rural-Urban Commuting Area (RUCA) codes. Results: Two hundred three unique patients met inclusion criteria. Of these, 36.5% (n = 74) lived in non-urban areas and 63.5% (n = 129) lived in urban areas. In the population of patients younger than 45 years of age who were not vaccinated for HPV prior to their VIN2 + diagnosis and treatment (n = 31), only 19.4% (n = 6) received at least one dose of the HPV vaccine in the adjuvant setting. Social vulnerability in housing and transportation was greatest in those living in rural areas. Conclusions: Extending the ACOG 2023 practice advisory recommendation for adjuvant HPV vaccination after excisional procedures for CIN2 + to encompass patients treated for VIN2 + may help reduce the burden of HPV-associated cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.